Some of these products are not FDA cleared. Please contact your sales representative for more information.
Product claims may differ from country to country based on regulations and product approvals.
Please contact your country representative for further details.
Sie möchten über die neuesten Nachrichten und wichtigsten Termine der B·R·A·H·M·S Aktiengesellschaft Informiert werden? Dann tragen Sie sich einfach in unser kostenloses News-Alert-System ein.
Eintragen / Abmelden
In the context of prenatal screening various examinations are carried out in order to detect early fetal abnormalities or chromosomal aberrations (trisomy 21). These include, among other things, blood tests and ultrasound examination (nuchal translucency measurement). By using the B·R·A·H·M·S Fast Screen pre I plus V 1.3 an individual risk regarding the most common chromosomal anomalies is calculated from various input parameters such as maternal age, gestational age, blood and ultrasound results as well as the medical history. The results of this combined analysis serve as a basis for further diagnostic measures.
With the Update B·R·A·H·M·S Fast Screen pre I plus V 1.3 is not only applicable for the first and second trimester screening but also for the so-called Integrated Sequential Screening. The results of the ultrasound examination in the first trimester (nuchal translucency measurement) are combined with the results of the blood tests in the second trimester. The license key for the first trimester and the Integrated Sequential Screening is only made available to doctors who are certified by the Fetal Medicine Foundation (FMF-Germany). Furthermore, the software offers the advantage of exporting the results into Excel, extracting data from the laboratory-information-system or saving them there. By that, the laboratory organization is optimized.